Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor (FcRn) ...

Anti-acetylcholine receptor antibody (AChR-Ab) titers and the AChR-Ab rates of change correlated with myasthenia gravis ...

Heightened focus on delays in diagnosing generalized myasthenia gravis (gMG) follows the promise of better results for some patients with newer treatments that include complement inhibitors and ...

In part 4 of our interview, we learn more about nipocalimab’s safety profile and how this investigative agent might address ...

COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission ...

Myasthenia Gravis is a long-term, autoimmune condition in which the communication between muscles and nerves is impaired due to the production of certain antibodies resulting in voluntary muscle ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...

THE occurrence of thyrotoxicosis in patients with myasthenia gravis is not rare, over 90 such cases having been reported since the turn of the century. 1,2 Various estimates place the incidence of ...

Welcome, everyone. I'm Dr. John Whyte, the Chief Medical Officer at WebMD. Today, I want to discuss myasthenia gravis. It's a rare autoimmune neuromuscular disease that causes weakness and fatigue ...

To learn this, the researchers measured the effect of Vyvgart using a test called the Myasthenia Gravis-Specific Activities of Daily Living scale (MG-ADL), which shows how gMG affects daily ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

The Neuromuscular Disease Center has a long history of providing excellent clinical care and research in myasthenia gravis. Myasthenia gravis is a chronic autoimmune disorder that causes muscle ...